Letter to the editor: Expanding DPYD genotyping panels beyond current guidelines—real‐world evidence and clinical–economic thoughts on inclusion of additional variants

Documenti analoghi

• Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers
  di: Andrej Belančić, et al.
  Pubblicazione: (2025)
• Costs of Treating Onasemnogene Abeparvovec‐Xioi‐Induced Liver Injury
  di: Andrej Belančić, et al.
  Pubblicazione: (2025)
• Letter to the editor: Personalized antihypertensive treatment—The role of body fat indices beyond body mass index
  di: Christina Antza, et al.
  Pubblicazione: (2024)
• Time to accelerate rare disease research: AI‐powered in silico trials, digital twin‐driven RCTs and decision‐grade real‐world evidence
  di: Andrej Belančić, et al.
  Pubblicazione: (2026)
• Methodological considerations on paracetamol pharmacokinetics in spinal muscular atrophy: A response to Zhao et al.
  di: Elvira Meni Maria Gkrinia, et al.
  Pubblicazione: (2025)